Results 61 to 70 of about 85,599,609 (253)

Asymmetric Structure‐Driven Functional Synergy: A Multistimuli‐Activated Janus Nanomotor for Self‐Amplifying NO Cascade Therapy

Advanced Science, EarlyView.
The Janus nanomotors leverage an “asymmetric structure‐driven functional synergy” strategy to orchestrate spatiotemporally coordinated catalytic functions, in situ self‐amplifying NO generation, and deep tumor penetration, thereby enabling controllable, sustained, and uniform NO generation within the tumor microenvironment.
Chengcheng Li, Yu Zhang, Yu Chen, Lingyun He, Xian Shen, Weijian Sun, Hongbo Zhang   +6 more
wiley   +1 more source

Loss of Intestinal MSTN Promotes GLP‐1 Secretion Through SGLT1 Palmitoylation

Advanced Science, EarlyView.
Intestinal MSTN deficiency enhances glucose‐stimulated GLP‐1 secretion and glucose tolerance in high‐fat diet‐fed mice. Mechanistically, loss of MSTN promotes YY1‐associated ZDHHC20 expression, increasing SGLT1 S‐palmitoylation at Cys301 and its plasma membrane localization in L cells.
Sheng‐Zhong Han, Shuang‐Yan Chang, Zhaobo Luo, Ke Sun, Biaohu Quan, Yanqiu Lv, Zhouyan Li, Xinyue Liu, Sitong Lv, Meifu Xuan, Xiaoyufan Xu, Xue Fang, Hang Chang, Rihuan Zhang, Xi‐Jun Yin, Lin‐Hu Quan, Jin‐Dan Kang   +16 more
wiley   +1 more source

Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms

Frontiers in Pharmacology, 2017
Diabetes mellitus has been demonstrated to be closely associated with osteoporosis. Accordingly, hypoglycemic therapy is considered effective in treating metabolic bone disease.
Yinqiu Yang, Chenhe Zhao, Jing Liang, Mingxiang Yu, Xinhua Qu   +4 more
doaj   +1 more source

Predictive Factors for Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2015
BackgroundPredictive factors for the efficacy of dipeptidyl peptidase-4 (DPP-4) inhibitors for lowering glycosylated hemoglobin (HbA1c) remain unclear in patients with type 2 diabetes mellitus.
Shusuke Yagi, Ken-ichi Aihara, Masashi Akaike, Daiju Fukuda, Hotimah Masdan Salim, Masayoshi Ishida, Tomomi Matsuura, Takayuki Ise, Koji Yamaguchi, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki, Tetsuzo Wakatsuki, Michio Shimabukuro, Toshio Matsumoto, Masataka Sata   +15 more
doaj   +1 more source

Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice.

, 2011
International audienceInhibition of dipeptidyl peptidase-4 (DPP-4) activity improves glucose homeostasis through a mode of action related to the stabilization of the active forms of DPP-4-sensitive hormones such as the incretins that enhance glucose ...
Pierre Cattan, Thierry Sulpice, Myriam Masseboeuf, Jens J. Holst, Waget, Aurélie, Holst, Jens Juul, Drucker, Daniel J, Magnan, Christophe, Rémy Burcelin, Sulpice, Thierry, Mélis Karaca, Adriano Maida, Castel, Julien, Maida, Adriano, Burcelin, Rémy, Mattieu Armanet, Cattan, Pierre, Julien Castel, Holst, Jens J, Celine Garret, Masseboeuf, Myriam, Armanet, Mattieu, Payros, Gaëlle, Cabou, Cendrine, Christophe Magnan, Cendrine Cabou, Aurélie Waget, Gaëlle Payros, Daniel J. Drucker, Garret, Celine, Karaca, Mélis   +30 more
core   +1 more source

Time course of the recovery of DPP-4 activity following dissociation of trelagliptin from the preformed DPP-4-inhibitor complex.

, 2016
A preformed enzyme-inhibitor complex (where [DPP-4] = 50 nmol/L and trelagliptin concentration is as shown in the plot) was diluted 50-fold into a solution containing 2 mmol/L GP-pNA substrate (approximately 17x Km).
Yoshinobu Kinugawa (3165234), Nobuhiro Nishigaki (2134261), Akiyoshi Tani (2231677), Hiroki Sano (2962497), Koji Takeuchi (469159), Charles E. Grimshaw (3165231), Andy Jennings (2235538), Hikaru Ueno (3165237), Takuo Kosaka (2231683), Lihong Shi (481066), Emiko Koumura (3165240), Ruhi Kamran (1786588)   +11 more
core   +1 more source

Funnel plot for mean difference (MD) in the change in HbA1c (DPP-4 inhibitor vs. placebo or no treatment).

, 2014
Funnel plot for mean difference (MD) in the change in HbA1c (DPP-4 inhibitor vs. placebo or no treatment).
Dongsheng Cheng (652883), Xiaoxia Wang (14667), Junhui Li (304434), Yumei Liu (286628), Yuqiang Chen (652884), Niansong Wang (304438), Yang Fei (504329)   +6 more
core   +1 more source

Trends in the utilization, expenditure and costs of noninsulin glucose‐lowering drugs in the Medicaid population: Steady increases in glucagon‐like peptide‐1 receptor agonist and sodium–glucose transporter‐2 inhibitor use, prices and expenditure

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to analyse changes in the utilization, expenditure and average cost of noninsulin glucose‐lowering drugs (GLDs) between 2008 and 2023. Methods This was a retrospective observational study of 2008–2023 data from the National Medicaid State Drug Utilization database.
Rawan O. Almadfaa
wiley   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Teneligliptin: a DPP-4 inhibitor for the treatment of type 2 diabetes

, 2013
Miyako KishimotoDepartment of Diabetes and Metabolic Medicine, Center Hospital, Tokyo, Japan; Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, JapanAbstract: Dipeptidyl peptidase-
Kishimoto M
core